Litcius/Paper detail

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial

Per Fransson, Per Nilsson, Adalsteinn Gunnlaugsson, L. Beckman, Björn Tavelin, David Norman, Camilla Thellenberg‐Karlsson, Morten Høyer, Magnus Lagerlund, Jon Kindblom, Claes Ginman, Bengt Johansson, Kirsten Björnlinger, M. Seke, Måns Agrup, Björn Zackrisson, Elisabeth Kjellén, Lars Franzén, Anders Widmark

2021The Lancet Oncology157 citationsDOI

Topics & Concepts

MedicineProstate cancerRadiation therapyQuality of life (healthcare)ProstateLymph nodeRandomized controlled trialStage (stratigraphy)Dose fractionationUrologyCancerInternal medicineOncologySurgeryNursingPaleontologyBiologyProstate Cancer Diagnosis and TreatmentProstate Cancer Treatment and ResearchAdvanced Radiotherapy Techniques
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial | Litcius